Drug Profile
Dermal replacement - Organogenesis
Alternative Names: Vitrix™Latest Information Update: 14 Dec 2018
Price :
$50
*
At a glance
- Originator Organogenesis
- Developer Novartis; Organogenesis
- Class
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic foot ulcer; Wounds
Most Recent Events
- 10 Dec 2018 As part of merger, Organogenesis became a subsidiary of Organogenesis Holdings (formerly Avista Healthcare Public)
- 23 May 2003 This product is still in active development
- 08 Aug 2001 Investigation in Diabetic foot ulcer in USA (Intralesional)